YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
The available CDE acceptance records list 333 drug applications between 16 November 2026 and 22 November 2026 (data as of 23 November 2026). Of these, generic applications numbered 57, covering 41 drug names.
2026/11/16 – 2026/11/22
- New acceptances this week
- 333
- Drugs with new generic filings (by drug name, de-duplicated)
- 41
- Accepted this week, now under review
- 333
DefinitionAcceptance numbers accepted this week that are still on CDE's under-review list at the data cut-off; counted by acceptance date.
Names with a public page are linked.
New acceptances this week
By application type and drug type
333filings, 57 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 176 |
| New drug | 61 |
| Generic | 57 |
| Import | 31 |
| Import re-registration | 7 |
| Unspecified | 1 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 178 |
| TCM | 75 |
| Therapeutic biologic | 68 |
| Unspecified | 5 |
| Biologic | 5 |
| Prophylactic biologic | 2 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
41 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 司美格鲁肽注射液 · No verified English name | 5 | 1 | 99 |
| 2 | Mirogabalin Besilate Tablets | 3 | 2 | 64 |
| 3 | Ambroxol Hydrochloride Oral Solution | 3 | 1 | 49 |
| 4 | Rosuvastatin Calcium and Ezetimibe Tablets (I) | 2 | 2 | 7 |
| 5 | 二硫化硒洗剂 · No verified English name | 2 | 1 | 16 |
| 6 | Brexpiprazole Orally Disintegrating Tablets | 2 | 1 | 12 |
| 7 | 恩那度司他片 · No verified English name | 2 | 1 | 2 |
| 8 | Topiramate Tablets | 2 | 1 | 2 |
| 9 | Sildenafil Citrate Tablets | 2 | 1 | 14 |
| 10 | Polyvinyl Alcohol Eye Drops | 2 | 1 | 26 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
206 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | Henan Pu Rui Pharma Co., Ltd. romanized | 14 | 8 | 0 |
| 2 | Eli Lilly and Company | 6 | 4 | 0 |
| 3 | Novo Nordisk A/S | 6 | 1 | 0 |
| 4 | Xiamen Te Bao Bio Gong Cheng Co., Ltd. romanized | 6 | 1 | 0 |
| 5 | Suzhou Te Rui Pharma Co., Ltd. romanized | 5 | 1 | 5 |
| 6 | Sichuan Sheng Tong Yuan Pharmaceutical Group Co., Ltd. romanized | 4 | 4 | 0 |
| 7 | Pfizer Inc. | 4 | 3 | 0 |
| 8 | Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized | 4 | 3 | 0 |
| 9 | Boehringer Ingelheim International GmbH | 4 | 1 | 0 |
| 10 | CSL Behring GmbH | 4 | 1 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Based on changes in CDE's under-review list
- Entered review this week
- 333
- Left the under-review list this week
- 538
Of these, NMPA published approval-document delivery for 281 (including 277 supplemental applications, not counted as new marketing approvals) and notification delivery for 19; the outcome of the other 238 is to be checked.
Most filings leaving review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized | 11 | 2 |
| 2 | Mu Dan Jiang Ling Tai Pharma Co., Ltd. romanized | 9 | 9 |
| 3 | Luo Yang Yi Long Pharma Co., Ltd. romanized | 7 | 7 |
| 4 | Guangdong Tai En Kang Pharmaceutical Factory Co., Ltd. romanized | 6 | 2 |
| 5 | Eli Lilly and Company | 6 | 1 |
| 6 | Hybio Pharmaceutical Co.,Ltd. | 6 | 1 |
| 7 | Qinghai Qi Ying Han Cang Biopharmaceutical Co., Ltd. romanized | 5 | 5 |
| 8 | Shenyang Xing Qi Yan Yao Co., Ltd. romanized | 5 | 2 |
| 9 | Guangzhou Jia Yue Pharmaceuticals Technology Co., Ltd. romanized | 5 | 1 |
| 10 | Sichuan Sheng Tong Yuan Pharmaceutical Group Co., Ltd. romanized | 4 | 4 |
Most filings entering review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Henan Pu Rui Pharma Co., Ltd. romanized | 14 | 8 |
| 2 | Eli Lilly and Company | 6 | 4 |
| 3 | Novo Nordisk A/S | 6 | 1 |
| 4 | Xiamen Te Bao Bio Gong Cheng Co., Ltd. romanized | 6 | 1 |
| 5 | Suzhou Te Rui Pharma Co., Ltd. romanized | 5 | 1 |
| 6 | Sichuan Sheng Tong Yuan Pharmaceutical Group Co., Ltd. romanized | 4 | 4 |
| 7 | Pfizer Inc. | 4 | 3 |
| 8 | Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized | 4 | 3 |
| 9 | Boehringer Ingelheim International GmbH | 4 | 1 |
| 10 | CSL Behring GmbH | 4 | 1 |
DefinitionEntered review = acceptance numbers first listed on CDE's under-review list this week, excluding numbers already listed on the record start date (2026/10/22). Left review = acceptance numbers last listed this week and no longer listed at the data cut-off; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
99 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2026/11/20Import · Class 1 | IPN60340注射液 · No verified English nameJXSL2600326 | IPSEN PHARMA; Ipsen (Shanghai) Innovation Pharmaceutical Co. Ltd |
| 2026/11/20Import · Class 2.2 | 注射用维恩妥尤单抗 · No verified English nameJXSL2600325 | Pfizer Inc.; Astellas (China) Investment Co. Ltd. |
| 2026/11/20Import · Class 2.2 | 注射用维恩妥尤单抗 · No verified English nameJXSL2600324 | Pfizer Inc.; Astellas (China) Investment Co. Ltd. |
| 2026/11/20Import · Class 1 | Duvakitug注射液 · No verified English nameJXSL2600323 | Sanofi-Aventis Recherche & Développement; Sanofi (China) Investment Co. Ltd. |
| 2026/11/20Generic · Class 3 | Vardenafil Hydrochloride Orally disintegrating TabletsCYHS2602862 | Shandong Loncom Pharmaceutical Co., Ltd. |
| 2026/11/20Generic · Class 3 | Diphenhydramine Hydrochloride TabletsCYHS2602861 | Jiangsu Vanguard Pharmaceutical Co., Ltd. |
| 2026/11/20Generic · Class 3 | Sivelestat Sodium for InjectionCYHS2602860 | Nanjing En Tai Pharmaceuticals Technology Co., Ltd. romanized; Jiangsu Hai An Pharma Co., Ltd. romanized |
| 2026/11/20New drug · Class 1 | 注射用BL-M11D1 · No verified English nameCXSL2601297 | Chengdu Bai Li Duo Te Bio Pharma Co., Ltd. romanized; Sichuan Baili Pharmaceutical Co., Ltd. |
| 2026/11/20New drug · Class 1 | RXIM002 · No verified English nameCXSL2601296 | Zhuan Lu Ben (Shanghai) Bio Technology Co., Ltd. romanized |
| 2026/11/20New drug · Class 1 | 注射用Zilovertamab vedotin · No verified English nameCXSL2601295 | Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized |
| 2026/11/20New drug · Class 1 | 注射用MK-1045 · No verified English nameCXSL2601294 | Mo Sha Dong Research and Development (Zhongguo) Co., Ltd. romanized |
| 2026/11/20New drug · Class 1 | IB101注射液 · No verified English nameCXSL2601293 | Xi Hu Laboratory Technology (Hangzhou) Co., Ltd. romanized |
| 2026/11/20New drug · Class 1 | IBI3001 · No verified English nameCXSL2601292 | Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized |
| 2026/11/20New drug · Class 2.4 | 海曲泊帕乙醇胺片 · No verified English nameCXHS2600158 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd. |
| 2026/11/20New drug · Class Unmapped source value | 盐酸凯普拉生注射液 · No verified English nameCXHS2600157 | Nanjing Ke Chuang Pharmaceutical Co., Ltd. romanized |
| 2026/11/20New drug · Class 1 | 氘索昔替尼片 · No verified English nameCXHS2600156 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
| 2026/11/20New drug · Class 1 | 氘索昔替尼片 · No verified English nameCXHS2600155 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
| 2026/11/20New drug · Class 2.2 | GLX005 · No verified English nameCXHL2601461 | YABAO PHARMACEUTICAL GROUP CO.,LTD |
| 2026/11/20New drug · Class 2.3 | BPR-523-X片 · No verified English nameCXHL2601460 | Chengdu Brilliant Pharmaceutical Co., Ltd. |
| 2026/11/20New drug · Class 2.3 | BPR-523-X片 · No verified English nameCXHL2601459 | Chengdu Brilliant Pharmaceutical Co., Ltd. |
| 2026/11/20New drug · Class 1 | DAT-1604片 · No verified English nameCXHL2601458 | Zhejiang Dan Qing Pharma Technology Co., Ltd. romanized |
| 2026/11/20New drug · Class 1 | DAT-1604片 · No verified English nameCXHL2601457 | Zhejiang Dan Qing Pharma Technology Co., Ltd. romanized |
| 2026/11/19Generic · Class 3 | Colistimethate Sodium for InjectionCYHS2602859 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; Sichuan Huiyu Pharmaceutical Co., Ltd. |
| 2026/11/19Generic · Class 3 | 司美格鲁肽注射液 · No verified English nameCYHS2602857 | Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized |
| 2026/11/19Generic · Class 3 | 司美格鲁肽注射液 · No verified English nameCYHS2602856 | Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized |
| 2026/11/19Generic · Class 3 | 司美格鲁肽注射液 · No verified English nameCYHS2602855 | Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized |
| Generic · Class 3 | 司美格鲁肽注射液 · No verified English name | — |
| Generic · Class 3 | 司美格鲁肽注射液 · No verified English name | — |
| 2026/11/19Generic · Class 3 | 盐酸氨酮戊酸颗粒剂 · No verified English nameCYHS2602848 | Shanghai Fu Dan Zhang Jiang Biopharmaceuticals Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | IBI363 · No verified English nameCXSL2601291 | Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized |
69 more not listed (at most 30 rows).
For some entries, the drug or company page limits access to the acceptance date, filing number and applicants.
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.